Progyny (NASDAQ:PGNY) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Progyny (NASDAQ:PGNY) issued its quarterly earnings data on Wednesday. The company reported $0.03 earnings per share for the quarter, beating analysts’ consensus estimates of $0.02 by $0.01, Briefing.com reports. The company had revenue of $61.20 million for the quarter, compared to the consensus estimate of $60.83 million. The firm’s quarterly revenue was up 120.1% compared to the same quarter last year. Progyny updated its Q4 guidance to $0.01 EPS.

Shares of PGNY stock opened at $26.34 on Friday. Progyny has a 1-year low of $13.29 and a 1-year high of $29.29.

In other Progyny news, Director Norman Payson sold 568,994 shares of the company’s stock in a transaction that occurred on Tuesday, October 29th. The shares were sold at an average price of $16.39, for a total transaction of $9,325,811.66. Also, EVP Karin Ajmani sold 384,003 shares of the firm’s stock in a transaction on Tuesday, October 29th. The stock was sold at an average price of $16.39, for a total transaction of $6,293,809.17. Insiders have sold a total of 1,933,004 shares of company stock worth $32,258,136 over the last ninety days.

A number of equities analysts have commented on PGNY shares. Piper Jaffray Companies began coverage on shares of Progyny in a report on Wednesday, November 27th. They issued an “overweight” rating and a $33.00 target price for the company. JPMorgan Chase & Co. began coverage on shares of Progyny in a report on Wednesday, November 27th. They issued an “overweight” rating and a $26.00 price target on the stock. Citigroup began coverage on shares of Progyny in a research report on Wednesday, November 27th. They issued a “buy” rating and a $30.00 price objective on the stock. Svb Leerink began coverage on shares of Progyny in a research note on Tuesday, November 19th. They set an “outperform” rating and a $28.00 price objective for the company. Finally, Goldman Sachs Group began coverage on shares of Progyny in a research report on Tuesday, November 19th. They set a “buy” rating and a $33.00 target price for the company. Six investment analysts have rated the stock with a buy rating, Progyny currently has an average rating of “Buy” and a consensus target price of $29.67.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.

Further Reading: What are trading strategies for the 52-week high/low?

Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.